5 Paul Tudor Jones II Abivax Trades
Paul Tudor Jones II acquired 102k Abivax shares worth $10.1M. That's 0.05% of their equity portfolio (431st largest holding). The first Abivax trade was made in Q4 2023. Since then Paul Tudor Jones II bought shares two more times and sold shares on two occasions. The investor's estimated purchase price is $10.2M, resulting in a loss of 1.5%.
Avg closing price
Price range
Increased shares by 256.1% (+73.1k shares)
Q1 2026
Avg closing price
$118.61
Price range
$101.50
-
$133.77
Sold 13.2% shares (-4.35k shares)
Q4 2025
Avg closing price
$109.36
Price range
$82.40
-
$145.31
New holding (+32.9k shares)
Q3 2025
Avg closing price
$60.79
Price range
$7.66
-
$90.00
Sold -24.5k shares
Q1 2024
Avg closing price
$12.89
Price range
$10.74
-
$14.98
New holding (+24.5k shares)
Q4 2023
Avg closing price
$10.19
Price range
$8.10
-
$11.40
News about Abivax - ADR and Paul Tudor Jones II
Le Journal des biotechs : Marc de Garidel (Abivax)
17/11/2023 10:20:00 : Dans ce numéro hors série du Journal des biotechs, Marc de Garidel, PDG d''Abivax vient faire le point sur la situation de la biotech a...
Analysis of Ongoing ABX203 Phase IIb/III Trial in Chronic Hepatitis B Virus Infection Shows Good Safety, but Primary Endpoint of Study is Unlikely to Be Reached
PARIS--(BUSINESS WIRE)--Regulatory News: ABIVAX (Paris:ABVX) (Euronext Paris: FR0012333284 – ABVX), an innovative company developing anti-viral therapies and...